U.S. Patent Office to Prioritize COVID-19 Products Subject to FDA Approval

The U.S. Patent and Trademark Office (USPTO) has implemented a pilot program to prioritize patent applications for COVID-19 products subject to FDA approval.

Products subject to FDA approval include but are not limited to NDAs, BLAs and Emergency Use Authorizations.

The USPTO will prioritize these reviews without any additional fees. It will initially limit the pilot to applications that qualify for either small-entity or micro-entity status.